We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in our Lung Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

story of the week
Published in Lung Cancer

Journal Scan / Research · November 08, 2022

Treatment Characteristics and Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy

Journal of Thoracic Oncology

 

Additional Info

Journal of Thoracic Oncology
Treatment Characteristics and Real-World Progression-Free Survival in Patients with Unresectable Stage III NSCLC who Received Durvalumab After Chemoradiotherapy: Findings from the PACIFIC-R Study
J Thorac Oncol 2022 Oct 25;[EPub Ahead of Print], N Girard, J Bar, P Garrido, MC Garassino, F McDonald, F Mornex, AR Filippi, HJM Smit, S Peters, JK Field, DC Christoph, A Sibille, R Fietkau, VD Haakensen, C Chouaid, B Markman, TJN Hiltermann, A Taus, W Sawyer, A Allen, P Chander, M Licour, B Solomon

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading